Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesús Troya

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
The Lancet. Infectious Diseases|June 12, 2015
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trialJosé A Perez-Molina, Rafael Rubio, Antonio Rivero, et al.
Plos One|June 15, 2018
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL studyJesús Troya, Rocio Montejano, Pablo Ryan, et al.
AIDS (London, England)|March 5, 2019
Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individualsJuan Berenguer, Ángela Gil-Martin, Inmaculada Jarrin, et al.
Viruses|February 28, 2023
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 PandemicLuis Buzón, Carlos Dueñas, Roberto Pedrero, et al.
AIDS Patient Care and Stds|April 6, 2018
Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 StudyAlicia González-Baeza, Helen Dolengevich-Segal, Ignacio Pérez-Valero, et al.
Plos One|February 10, 2017
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyJesús Troya, Pablo Ryan, Esteban Ribera, et al.
Plos One|October 12, 2016
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyJesús Troya, Pablo Ryan, Esteban Ribera, et al.
BMJ Open|November 11, 2020
Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series studyEva Jiménez, Mario Fontán-Vela, Jorge Valencia, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 15, 2021
HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterizationDaniel Valle-Millares, Óscar Brochado-Kith, Alicia Gómez-Sanz, et al.
Open Forum Infectious Diseases|September 23, 2022
Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418Alfonso Cabello-Úbeda, Alicia González Baeza, Jesús Troya García, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
The Lancet. Infectious Diseases|June 12, 2015
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trialJosé A Perez-Molina, Rafael Rubio, Antonio Rivero, et al.
Plos One|June 15, 2018
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL studyJesús Troya, Rocio Montejano, Pablo Ryan, et al.
AIDS (London, England)|March 5, 2019
Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individualsJuan Berenguer, Ángela Gil-Martin, Inmaculada Jarrin, et al.
Viruses|February 28, 2023
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 PandemicLuis Buzón, Carlos Dueñas, Roberto Pedrero, et al.
AIDS Patient Care and Stds|April 6, 2018
Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 StudyAlicia González-Baeza, Helen Dolengevich-Segal, Ignacio Pérez-Valero, et al.
Plos One|February 10, 2017
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyJesús Troya, Pablo Ryan, Esteban Ribera, et al.
Plos One|October 12, 2016
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyJesús Troya, Pablo Ryan, Esteban Ribera, et al.
BMJ Open|November 11, 2020
Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series studyEva Jiménez, Mario Fontán-Vela, Jorge Valencia, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 15, 2021
HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterizationDaniel Valle-Millares, Óscar Brochado-Kith, Alicia Gómez-Sanz, et al.
Open Forum Infectious Diseases|September 23, 2022
Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418Alfonso Cabello-Úbeda, Alicia González Baeza, Jesús Troya García, et al.
Pageof 6